NASDAQ:SYRE Spyre Therapeutics (SYRE) Stock Price, News & Analysis → The “Next Bitcoin”? 10 CENT Crypto Set to Explode (From True Market Insiders) (Ad) Free SYRE Stock Alerts $33.56 +1.09 (+3.36%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$32.50▼$34.3150-Day Range$20.41▼$45.3752-Week Range$2.66▼$47.97Volume225,967 shsAverage Volume302,338 shsMarket Capitalization$1.21 billionP/E RatioN/ADividend YieldN/APrice Target$39.20 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Get Spyre Therapeutics alerts: Email Address Spyre Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside16.8% Upside$39.20 Price TargetShort InterestBearish10.55% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.69Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.36) to ($2.52) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.64 out of 5 starsMedical Sector855th out of 915 stocksPharmaceutical Preparations Industry403rd out of 422 stocks 2.5 Analyst's Opinion Consensus RatingSpyre Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSpyre Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.55% of the float of Spyre Therapeutics has been sold short.Short Interest Ratio / Days to CoverSpyre Therapeutics has a short interest ratio ("days to cover") of 7.3.Change versus previous monthShort interest in Spyre Therapeutics has recently increased by 18.27%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSpyre Therapeutics does not currently pay a dividend.Dividend GrowthSpyre Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SYRE. Previous Next 2.6 News and Social Media Coverage News SentimentSpyre Therapeutics has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Spyre Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for SYRE on MarketBeat in the last 30 days. This is a decrease of -91% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Spyre Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Spyre Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.20% of the stock of Spyre Therapeutics is held by insiders.Percentage Held by Institutions80.39% of the stock of Spyre Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Spyre Therapeutics are expected to decrease in the coming year, from ($2.36) to ($2.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Spyre Therapeutics is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Spyre Therapeutics is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsThe Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. About Spyre Therapeutics Stock (NASDAQ:SYRE)Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.Read More SYRE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SYRE Stock News HeadlinesApril 23, 2024 | americanbankingnews.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Consensus Recommendation of "Buy" from AnalystsApril 20, 2024 | investing.comSpyre Therapeutics Inc (SYRE)April 28, 2024 | TradeSmith (Ad)The A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...April 17, 2024 | msn.comSpyre Therapeutics (SYRE) Price Target Increased by 5.00% to 42.84April 5, 2024 | markets.businessinsider.comBuy Rating Affirmed for Spyre Therapeutics on Promising mAb Dosing and Market PositioningApril 1, 2024 | prnewswire.comSpyre Therapeutics Announces Grants of Inducement AwardsMarch 25, 2024 | markets.businessinsider.comStrong Buy Rating for Spyre Therapeutics Based on Promising SPY001 Data and Financial PositionMarch 20, 2024 | investing.comSpyre Therapeutics secures $180 million in PIPE dealApril 28, 2024 | TradeSmith (Ad)The A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...March 18, 2024 | markets.businessinsider.comSpyre Therapeutics Privately Places $180 Mln Of Shares; Stock Up In Pre-MarketMarch 18, 2024 | msn.comSpyre Therapeutics climbs 5%, prices $180M private financingMarch 18, 2024 | prnewswire.comSpyre Therapeutics Announces $180 Million Private PlacementMarch 6, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Humana (HUM), Alnylam Pharma (ALNY) and Spyre Therapeutics (SYRE)March 4, 2024 | msn.comHere's What Could Help Spyre Therapeutics (SYRE) Maintain Its Recent Price StrengthMarch 2, 2024 | finanznachrichten.deSpyre Therapeutics, Inc.: Spyre Therapeutics Announces Grants of Inducement AwardsMarch 1, 2024 | prnewswire.comSpyre Therapeutics Announces Grants of Inducement AwardsMarch 1, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: GeoVax Labs (GOVX), Madrigal Pharmaceuticals (MDGL) and Spyre Therapeutics (SYRE)March 1, 2024 | markets.businessinsider.comBuy Rating for Spyre Therapeutics: Anticipated Clinical Trials and Strategic Advantages Propel OptimismMarch 1, 2024 | finanznachrichten.deSpyre Therapeutics, Inc.: Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 1, 2024 | markets.businessinsider.comTD Cowen Sticks to Its Buy Rating for Spyre Therapeutics (SYRE)February 29, 2024 | prnewswire.comSpyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateFebruary 26, 2024 | finance.yahoo.comSpyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care ConferenceFebruary 26, 2024 | prnewswire.comSpyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care ConferenceFebruary 8, 2024 | finance.yahoo.comSpyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis OrganisationFebruary 6, 2024 | markets.businessinsider.comSpyre Therapeutics Enhances Protection for Executives and BoardFebruary 6, 2024 | msn.comHere's Why Spyre Therapeutics (SYRE) Could be Great Choice for a Bottom FisherFebruary 6, 2024 | msn.comSpyre Therapeutics Announces Board Changes and Compensation UpdatesSee More Headlines Receive SYRE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spyre Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today4/28/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SYRE Previous SymbolNASDAQ:SYRE CUSIPN/A CIK1636282 Webwww.aeglea.com Phone512-942-2935Fax512-872-5121Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$39.20 High Stock Price Target$54.00 Low Stock Price Target$31.00 Potential Upside/Downside+16.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($75.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-338,790,000.00 Net MarginsN/A Pretax Margin-38,241.09% Return on EquityN/A Return on Assets-107.71% Debt Debt-to-Equity RatioN/A Current Ratio10.68 Quick Ratio10.68 Sales & Book Value Annual Sales$890,000.00 Price / Sales1,363.14 Cash FlowN/A Price / Cash FlowN/A Book Value($0.22) per share Price / Book-152.55Miscellaneous Outstanding Shares36,150,000Free Float33,910,000Market Cap$1.21 billion OptionableOptionable Beta2.88 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Cameron Turtle DPHIL (Age 34)Ph.D., CEO & Director Comp: $674.17kMr. Scott L. Burrows (Age 47)Chief Financial Officer Comp: $331.81kMs. Heidy Abreu King-Jones J.D. (Age 41)L.L.M., Chief Legal Officer & Corporate Secretary Comp: $568.87kDr. Janet Gunzner-Toste M.B.A.Ph.D., Senior Vice President of OperationsBrian ConnollyChief Technical OfficerMr. Eric McIntyreVice President of Finance & Investor RelationsMr. James MyersVice President of Quality & ComplianceDr. Kelly Boothe Ph.D.Senior Director of Corporate Communications & Investor RelationsDr. Justin LaFountaine Ph.D.Senior Vice President of Corporate DevelopmentMs. Melissa CooperSenior Vice President of PeopleMore ExecutivesKey CompetitorsLigand PharmaceuticalsNASDAQ:LGNDPacira BioSciencesNASDAQ:PCRXKiniksa PharmaceuticalsNASDAQ:KNSAVerona PharmaNASDAQ:VRNAPieris PharmaceuticalsNASDAQ:PIRSView All Competitors SYRE Stock Analysis - Frequently Asked Questions Should I buy or sell Spyre Therapeutics stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spyre Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SYRE shares. View SYRE analyst ratings or view top-rated stocks. What is Spyre Therapeutics' stock price target for 2024? 7 brokerages have issued twelve-month target prices for Spyre Therapeutics' shares. Their SYRE share price targets range from $31.00 to $54.00. On average, they expect the company's stock price to reach $39.20 in the next year. This suggests a possible upside of 16.8% from the stock's current price. View analysts price targets for SYRE or view top-rated stocks among Wall Street analysts. How have SYRE shares performed in 2024? Spyre Therapeutics' stock was trading at $21.52 at the start of the year. Since then, SYRE stock has increased by 55.9% and is now trading at $33.56. View the best growth stocks for 2024 here. When is Spyre Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our SYRE earnings forecast. How were Spyre Therapeutics' earnings last quarter? Spyre Therapeutics, Inc. (NASDAQ:SYRE) issued its earnings results on Thursday, February, 29th. The company reported ($2.28) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by $1.80. What ETFs hold Spyre Therapeutics' stock? ETFs with the largest weight of Spyre Therapeutics (NASDAQ:SYRE) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC).Invesco Dorsey Wright Healthcare Momentum ETF (PTH). How do I buy shares of Spyre Therapeutics? Shares of SYRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SYRE) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHis win rate puts Warren Buffett to shame… Investing DailyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBiden out June 13; Kamala won’t replace him?Paradigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
